Scientific American: Vessels of Death or Life – An article from Scientific American: “Angiogenesis – the formation of new blood vessels – might one day be manipulated to treat disorders from cancer to heart disease. First-generation drugs are now in the final phase of human testing.” (Rakesh K. Jain and Peter Carmeliet, 2001) (Just above Beginner’s Level)

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

1. INTRODUCTION

2. WHAT IS ANGIOGENESIS?

3. THE ANGIOGENIC-METASTATIC PATHWAY AS A

TARGET FOR ANTICANCER THERAPIES

4. NATURAL HEALTH PRODUCTS THAT INHIBIT

ANGIOGENESIS

5. CONCLUSION

6. REFERENCES

Abstract

An integrative approach for managing a patient with cancer should target the multiple biochemical and physiologic pathways that support tumor development and minimize normal-tissue toxicity. Angiogenesis is a key process in the promotion of cancer. Many natural health products that inhibit angiogenesis also manifest other anticancer activities. The present article focuses on products that have a high degree of anti-angiogenic activity, but it also describes some of the many other actions of these agents that can inhibit tumor progression and reduce the risk of metastasis. Natural health products target molecular pathways other than angiogenesis, including epidermal growth factor receptor, the HER2/neu gene, the cyclooxygenase-2 enzyme, the nuclear factor kappa-B transcription factor, the protein kinases, the Bcl-2 protein, and coagulation pathways.

the multiple effects of these agents, their future use for cancer therapy probably lies in synergistic combinations. During active cancer therapy, they should generally be evaluated in combination with chemotherapy and radiation. In this role, they act as modifiers of biologic response or as adaptogens, potentially enhancing the efficacy of the conventional therapies.

If you read about it and are interested, there is an invitational mailing list at http://www.ACOR.org .the Angio-Roundtable Mailing list… which discusses this cocktail and taking it and angiogenesis inhibitors. This Mailing list is not a chit chat list or emotional support list, but a subject oriented list. It is not a public list, membership is by invitation only. Bill Peeples is on this list as well as the LMS list. To join email privately to Bill: whpeeples@aol.com or Yvonne Cooper: ymccooper@yahoo.com or Tracey Snell: tjs@snagdata.com

Bill Peeples’ developed his cocktail about 12 years ago for his wife. It undergoes revision as more agents become available. It has not been proven of benefit, nor has it been NOT proven of benefit, but individual agents have had a LOT of research done on them.